Dynavax Technologies - DVAX Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares.
View DVAX analyst ratings or view top-rated stocks.

3 analysts have issued 1 year price objectives for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $27.00. On average, they predict the company's stock price to reach $24.33 in the next year. This suggests a possible upside of 144.3% from the stock's current price.
View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts.

Dynavax Technologies' stock was trading at $10.64 at the beginning of the year. Since then, DVAX stock has decreased by 6.4% and is now trading at $9.96.
View the best growth stocks for 2023 here.

Dynavax Technologies saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 16,160,000 shares, a decrease of 13.3% from the February 13th total of 18,640,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is currently 10.0 days.
View Dynavax Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our DVAX earnings forecast.

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company had revenue of $108.27 million for the quarter, compared to analyst estimates of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 65.26% and a net margin of 40.56%. During the same quarter in the previous year, the business earned ($0.15) EPS.

ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco S&P SmallCap Health Care ETF (PSCH), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Franklin Genomic Advancements ETF (HELX).

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Chicago Capital LLC (4.59%), Fisher Asset Management LLC (3.20%), Blair William & Co. IL (1.95%), Geode Capital Management LLC (1.74%), Morgan Stanley (1.60%) and Dimensional Fund Advisors LP (1.40%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends.

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DVAX stock can currently be purchased for approximately $9.96.

Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.27 billion and generates $722.68 million in revenue each year. The biopharmaceutical company earns $293.16 million in net income (profit) each year or $1.97 on an earnings per share basis.

The company employs 311 workers across the globe.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327.